ES2092698T3 - Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm). - Google Patents

Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm).

Info

Publication number
ES2092698T3
ES2092698T3 ES92918792T ES92918792T ES2092698T3 ES 2092698 T3 ES2092698 T3 ES 2092698T3 ES 92918792 T ES92918792 T ES 92918792T ES 92918792 T ES92918792 T ES 92918792T ES 2092698 T3 ES2092698 T3 ES 2092698T3
Authority
ES
Spain
Prior art keywords
alpha interferon
diabetes mellitus
dependent diabetes
insulin dependent
iddm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918792T
Other languages
English (en)
Inventor
Timothy Andrew Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2092698T3 publication Critical patent/ES2092698T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EL MELLITUS DE LA DIABETES DEPENDIENTE DE LA INSULINA SE TRATA A BASE DE ADMINISTRAR A UN PACIENTE DURANTE LAS ETAPAS DE ATAQUE INICIALES O PRECLINICAS DE LA ENFERMEDAD UNA DOSIS TERAPEUTICAMENTE EFECTIVA DE UN ANTAGONISTA DE LA ALFA INTERFERONA. ENTRE LOS ANTAGONISTAS ADECUADOS CABE INCLUIR LOS ANTICUERPOS NEUTRALIZANTES DE LA ANTI-ALFA INTERFERONA, ANTICUERPOS NEUTRALIZANTES DIRIGIDOS CONTRA LOS POLIPEPTIDOS RECEPTORES DE LA ALFA INTERFERONA, PREPARACIONES SOLUBLES DEL RECEPTOR DE LA ALFA INTERFERONA, FRAGMENTOS DE ALFA INTERFERONA Y SIMILARES.
ES92918792T 1991-08-30 1992-08-19 Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm). Expired - Lifetime ES2092698T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75230991A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
ES2092698T3 true ES2092698T3 (es) 1996-12-01

Family

ID=25025756

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92918792T Expired - Lifetime ES2092698T3 (es) 1991-08-30 1992-08-19 Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm).

Country Status (8)

Country Link
EP (1) EP0601052B1 (es)
JP (1) JPH06510061A (es)
AT (1) ATE144149T1 (es)
DE (1) DE69214656T2 (es)
DK (1) DK0601052T3 (es)
ES (1) ES2092698T3 (es)
GR (1) GR3022092T3 (es)
WO (1) WO1993004699A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7782894A (en) * 1993-09-17 1995-04-03 Laboratoire Europeen De Biotechnologie S.A. Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
EP0859633A2 (en) * 1996-08-16 1998-08-26 Kurt B. Osther Method for treating diabetes
AU761577C (en) 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
ES2313039T3 (es) 2003-04-23 2009-03-01 Medarex, Inc. Composiciones y procedimientos para la terapia de enfermedad inflamatoria intestinal.
WO2005059106A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Interferon alpha antibodies and their uses
RU2600884C2 (ru) 2004-06-21 2016-10-27 Е. Р. Сквибб энд Сонз, Эл,Эл.Си Антитела рецептора 1 интерферона альфа и их применение
JP5837730B2 (ja) 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα２（ＩＦＮα２）変異体
RU2532832C2 (ru) 2008-05-07 2014-11-10 Аргос Терапьютикс, Инк. Гуманизированные антитела против альфа-интерферона человека
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon

Also Published As

Publication number Publication date
ATE144149T1 (de) 1996-11-15
EP0601052A1 (en) 1994-06-15
DE69214656T2 (de) 1997-03-13
GR3022092T3 (en) 1997-03-31
EP0601052B1 (en) 1996-10-16
DK0601052T3 (da) 1996-11-18
WO1993004699A1 (en) 1993-03-18
JPH06510061A (ja) 1994-11-10
DE69214656D1 (de) 1996-11-21

Similar Documents

Publication Publication Date Title
ES2092698T3 (es) Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm).
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
RU2000100346A (ru) Способы лечения ожирения
ES2169021T3 (es) Uso de un peptido de mbp para la preparacion de un medicamento para el tratamiento de la esclerosis multiple.
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
DK0432400T3 (da) Farmakologisk aktiv forbindelse BPC, fremgangsmåde til fremstilling heraf og dens anvendelse indenfor terapien
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
Stuart et al. Failure of calcitonin to inhibit collagen-induced arthritis in rats
RU2003344C1 (ru) Способ лечени ожоговой болезни
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
MAKI et al. Studies on effects of paromomycin sulphate, bithionol, mebendazole and flubendazole in the treatment of mice infected with plerocercoids of Diphyllobothrium erinacei
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
SE8903117D0 (sv) Laekemedel omfattande antamanid
UA10254A (uk) Спосіб лікування цукрового діабету

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 601052

Country of ref document: ES